- Home
- ELAB vs GLTO Comparison
ELAB vs GLTO Comparison
Compare ELAB & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELAB
- GLTO
- Stock Information
- Founded
- ELAB 2020
- GLTO 2011
- Country
- ELAB United States
- GLTO Denmark
- Employees
- ELAB N/A
- GLTO N/A
- Industry
- ELAB
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- ELAB
- GLTO Health Care
- Exchange
- ELAB Nasdaq
- GLTO Nasdaq
- Market Cap
- ELAB 6.6M
- GLTO 6.5M
- IPO Year
- ELAB 2023
- GLTO 2020
- Fundamental
- Price
- ELAB $4.55
- GLTO $3.23
- Analyst Decision
- ELAB
- GLTO Buy
- Analyst Count
- ELAB 0
- GLTO 1
- Target Price
- ELAB N/A
- GLTO $10.00
- AVG Volume (30 Days)
- ELAB 418.9K
- GLTO 719.8K
- Earning Date
- ELAB 05-14-2025
- GLTO 03-19-2025
- Dividend Yield
- ELAB N/A
- GLTO N/A
- EPS Growth
- ELAB N/A
- GLTO N/A
- EPS
- ELAB N/A
- GLTO N/A
- Revenue
- ELAB N/A
- GLTO N/A
- Revenue This Year
- ELAB N/A
- GLTO N/A
- Revenue Next Year
- ELAB N/A
- GLTO N/A
- P/E Ratio
- ELAB N/A
- GLTO N/A
- Revenue Growth
- ELAB N/A
- GLTO N/A
- 52 Week Low
- ELAB $3.88
- GLTO $2.79
- 52 Week High
- ELAB $1,064.00
- GLTO $19.75
- Technical
- Relative Strength Index (RSI)
- ELAB 35.23
- GLTO 40.83
- Support Level
- ELAB $4.08
- GLTO $2.79
- Resistance Level
- ELAB $5.07
- GLTO $7.30
- Average True Range (ATR)
- ELAB 0.86
- GLTO 0.78
- MACD
- ELAB 0.26
- GLTO -0.17
- Stochastic Oscillator
- ELAB 14.62
- GLTO 9.76
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.